Information Provided By:
Fly News Breaks for January 5, 2017
ALXN
Jan 5, 2017 | 06:09 EDT
Citi analyst Robyn Karnauskas calls Alexion Pharmaceuticals a "high conviction" buy idea for 2017 after the company disclosed its quarterly filing for Q3 with no restatement. The analyst is "encouraged" by the audit committee's findings and believes an overhang is now lifted. Karnauskas thinks consensus 2017 numbers for Soliris are achievable and keeps a Buy rating on Alexion with a $173 price target.
News For ALXN From the Last 2 Days
There are no results for your query ALXN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.